ArticleAdvances in therapy2022

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.

Takashi Kadowaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.